GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carilex Medical Inc (ROCO:7726) » Definitions » Debt-to-EBITDA

Carilex Medical (ROCO:7726) Debt-to-EBITDA : 1.24 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Carilex Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Carilex Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$66.4 Mil. Carilex Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$2.2 Mil. Carilex Medical's annualized EBITDA for the quarter that ended in Jun. 2024 was NT$55.3 Mil. Carilex Medical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 1.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Carilex Medical's Debt-to-EBITDA or its related term are showing as below:

ROCO:7726' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.85   Med: 1.24   Max: 1.66
Current: 1.09

During the past 4 years, the highest Debt-to-EBITDA Ratio of Carilex Medical was 1.66. The lowest was 0.85. And the median was 1.24.

ROCO:7726's Debt-to-EBITDA is ranked better than
57.77% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs ROCO:7726: 1.09

Carilex Medical Debt-to-EBITDA Historical Data

The historical data trend for Carilex Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carilex Medical Debt-to-EBITDA Chart

Carilex Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
0.85 1.66 1.56 0.92

Carilex Medical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial - 1.62 0.92 1.03 1.24

Competitive Comparison of Carilex Medical's Debt-to-EBITDA

For the Medical Devices subindustry, Carilex Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carilex Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Carilex Medical's Debt-to-EBITDA falls into.



Carilex Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Carilex Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(65.161 + 7.249) / 78.843
=0.92

Carilex Medical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(66.399 + 2.156) / 55.268
=1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Carilex Medical  (ROCO:7726) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Carilex Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Carilex Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Carilex Medical Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No.77, Keji 1st Road, Guishan District, Taoyuan, TWN, 33383
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.

Carilex Medical Headlines

No Headlines